Table 1 Clinicopathological characteristics of recruited patients
Variable | Before PSM | p value | After PSM | p value | ||
|---|---|---|---|---|---|---|
Nonlocal treatment (n = 5322,73.4%) | Local treatment (n = 1933,26.6%) | Nonlocal treatment (n = 1923,50%) | Local treatment (n = 1923,50%) | |||
Age(years) | < 0.001 | 0.012 | ||||
≤ 65 | 1807 (34.0) | 797 (41.2) | 711 (37.0) | 787 (40.9) | ||
> 65 | 3515 (66.0) | 1136 (58.8) | 1212 (63.0) | 1136 (59.1) | ||
Race | 0.091 | 0.027 | ||||
White | 4014 (75.4) | 1495 (77.3) | 1543 (80.2) | 1487 (77.3) | ||
Others | 1308 (24.6) | 438 (22.7) | 380 (19.8) | 436 (22.7) | ||
PSA(ng/ml) | < 0.001 | 0.001 | ||||
PSA ≤ 20 | 1182 (22.2) | 678 (35.1) | 573 (29.8) | 668 (34.7) | ||
20 < PSA ≤ 50 | 992 (18.6) | 320 (16.6) | 399 (20.7) | 320 (16.6) | ||
50 < PSA ≤ 80 | 502 (9.4) | 156 (8.1) | 167 (8.7) | 156 (8.1) | ||
PSA > 80 | 2646 (49.7) | 779 (40.3) | 784 (40.8) | 779 (40.5) | ||
Gleason | < 0.001 | 0.031 | ||||
< 7 | 142 (2.7) | 70 (3.6) | 53 (2.8) | 66 (3.4) | ||
7 | 799 (15.0) | 358 (18.5) | 300 (15.6) | 352 (18.3) | ||
> 7 | 4381 (82.3) | 1505 (77.9) | 1570 (81.6) | 1505 (78.3) | ||
T-stage | < 0.001 | 0.003 | ||||
T1 | 2046 (38.4) | 645 (33.4) | 545 (28.3) | 645 (33.5) | ||
T2 | 1921 (36.1) | 689 (35.6) | 766 (39.8) | 687 (35.7) | ||
T3 | 745 (14.0) | 354 (18.3) | 345 (17.9) | 351 (18.3) | ||
T4 | 610 (11.5) | 245 (12.7) | 267 (13.9) | 240 (12.5) | ||
N-stage | 0.896 | 0.732 | ||||
N0 | 3576 (67.2) | 1302 (67.4) | 1283 (66.7) | 1293 (67.2) | ||
N1 | 1746 (32.8) | 631 (32.6) | 640 (33.3) | 630 (32.8) | ||
M-stage | 0.211 | 0.017 | ||||
M1NOS | 154 (2.9) | 54 (2.8) | 28 (1.5) | 54 (2.8) | ||
M1a | 377 (7.1) | 132 (6.8) | 136 (7.1) | 132 (6.9) | ||
M1b | 4077 (76.6) | 1450 (76.6) | 1493 (77.6) | 1446 (75.2) | ||
M1c | 714 (13.4) | 297 (15.4) | 266 (13.8) | 291 (15.1) | ||